CD4+CD8-, CD4+CD8+, CD4-CD8+, and CD4-CD8- phenotypes were observed in 94%, 3%, 0%, and 3% of primary SS cases, respectively, and in 13%, 0%, 87%, and 0% of T-LGL leukemia cases, respectively. Here, CD8A is linked to synovial sarcoma.